Big pharma, Partnering

Big pharma partneirng ties: Shionogi in a pact with GSK & Viiv Healthcare for dolutegravir

Posted on 30 October 2012

Tags: , ,

Shionogi, a top 50 big pharma company will take a 10 percent stake in Viiv Healthcare, a AIDS drug joint venture between GlaxoSmithKline and Pfizer in a pharma partnering pact,  in exchange for its rights to the drug Dolutegravir.
Shionogi, which will retain intellectual property rights to the drug, will gain one Viiv board seat and receive royalties of 15 percent to 19 percent on sales of Dolutegravir and related products.

Financial terms of the pharma partnering pact were not disclosed.

For further deal information visit Current Agreements (subscription required)



Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies

Report: Practical Guide to Finding Partners

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Shionogi

Related reports: Bigpharma Partnering Yearbook 2013

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply